Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722311 | 0.83 | CES1 (0.49) | ADRB2ADRB1KCNH2HDAC1HDAC2 | |
| SCHEMBL14850528 | 0.83 | ADRB2 (0.40) | ADRB2ADRB1HDAC1HDAC2 | |
| SCHEMBL16367918 | 0.83 | CES1 (0.49) | ADRB2ADRB1KCNH2HDAC1HDAC2 | |
| SCHEMBL2008716 | 0.83 | ADRB2 (0.42) | ADRB2ADRB1HDAC1HDAC2 | |
| SCHEMBL244848 | 0.83 | ADRB2 (0.40) | ADRB2ADRB1HDAC1HDAC2 | |
| SCHEMBL16367914 | 0.83 | ADRB2 (0.40) | ADRB2ADRB1CA2HDAC1HDAC2 | |
| SCHEMBL2012648 | 0.82 | KIF11 (0.47) | KIF11SLC7A5KCNH2HDAC1HDAC2 | |
| Ammonia Solution, Strong SCHEMBL1723857 | 0.82 | CES1 (0.47) | ADRB2ADRB1KCNH2HDAC1HDAC2 | |
| SCHEMBL8670825 | 0.80 | HDAC1 (0.50) | ADRB2ADRB1HDAC1HDAC2 | |
| SCHEMBL14850524 | 0.80 | ADRB2 (0.42) | ADRB2ADRB1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763967-A1 | PROCESS FOR PREPARING 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | Almirall, S.A. (ES) | 2014-08-13 | — | — | EP | claimed |
| US-8524908-B2 | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one | ALMIRALL, S.A. (ES) | 2013-09-03 | — | — | US | claimed |
| WO-2013050375-A1 | PROCESS FOR PREPARING 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | WO | claimed |
| EP-2578570-A1 | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. | Almirall, S.A. (ES) | 2013-04-10 | — | — | EP | claimed |
| US-20120004414-A1 | PROCESS FOR MANUFACTURING 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE | ALMIRALL, S.A. (ES) | 2012-01-05 | — | — | US | claimed |
| EP-2228368-A1 | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one | Almirall, S.A. (ES) | 2010-09-15 | — | — | EP | claimed |
| WO-2022172292-A1 | A PROCESS FOR PREPARING ABEDITEROL AND INTERMEDIATES THEREOF | GBR LABORATORIES PRIVATE LIMITED (IN) | 2022-08-18 | — | — | WO | disclosed |
| US-9108918-B2 | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate | ALMIRALL, S.A. (ES) | 2015-08-18 | — | — | US | disclosed |
| US-9108918-B2 | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate | ALMIRALL, S.A. (ES) | 2015-08-18 | — | — | US | disclosed |
| US-9108918-B2 | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate | ALMIRALL, S.A. (ES) | 2015-08-18 | — | — | US | disclosed |
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | ALMIRALL, S.A. (ES) | 2015-01-08 | — | — | US | disclosed |
| EP-2263998-A1 | Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor | Almirall S.A. (ES) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010102831-A1 | PROCESS FOR MANUFACTURING 5-(2-{[6-(2,2-DIFLUORO-2-PHENYIETHOXY) HEXYL]AMINO}-L- HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE. | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | WO | disclosed |
| EP-2228368-A1 | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one | Almirall, S.A. (ES) | 2010-09-15 | — | — | EP | disclosed |
| EP-2228368-A1 | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one | Almirall, S.A. (ES) | 2010-09-15 | — | — | EP | disclosed |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| EP-1885684-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA-2 ADRENERGIC RECEPTOR | Laboratorios Almirall, S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006122788-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE β2 ADRENERGIC RECEPTOR | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011769-A1 | PROCESS FOR PREPARING 5-(2--1(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE VIA A NOVEL INTERMEDIATE | UGT1A8, UGT1A1, UGT8 | KIF11 1414/4885ADRB2 411/4885ADRB1 493/4885 |
| US-20120004414-A1 | PROCESS FOR MANUFACTURING 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE | HAX1, CYP4B1, CYP4X1 | KIF11 4364/4885ADRB2 751/4885ADRB1 945/4885 |
| US-20090042933-A1 | Derivatives of 4-(2-amino -1-hydroxyethyl)phenol as agonists of the Beta2 adrenergic receptor | ADRB2, ADRA2C, ADRB1 | KIF11 3154/4885ADRB2 1/4885ADRB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.